Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous endometrial functional cells exosome is an experimental cell-free regenerative therapy being investigated for the treatment of thin endometrium and intrauterine adhesions (Asherman's syndrome). The therapy involves isolating functional cells, typically mesenchymal stem cells (EnMSCs), from a patient's own endometrial tissue, culturing them to collect secreted extracellular vesicles (exosomes), and then administering these exosomes back to the patient via intrauterine infusion. These exosomes carry a bioactive cargo of miRNAs, proteins, and growth factors that promote endometrial cell proliferation, stimulate angiogenesis, and modulate the local inflammatory environment to facilitate tissue repair and improve uterine receptivity for embryo implantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous endometrial functional cells exosome.